Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Pancreatic cancer survival extended by over a year with chemotherapy regimen

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 569
Rating:

Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Dr Conroy presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a phase III randomised trial in which patients with surgically resected pancreatic cancer were treated with mFOLFIRINOX.

Compared to those receiving the current standard of care, gemcitabine, trial participants had a median disease free survival of 21.6months v 12.8months, and a median overall survival of 54.4 months v 35 months.

For more on these findings, watch his interview with ecancer, or read news coverage here.

View the slides here.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation